Both Tenax Therapeutics Inc. (NASDAQ:TENX) and Neuralstem Inc. (NASDAQ:CUR) are each others competitor in the Biotechnology industry. Thus the contrast of their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Table 1 highlights Tenax Therapeutics Inc. and Neuralstem Inc.s gross revenue, earnings per share and valuation.

Profitability

Table 2 shows Tenax Therapeutics Inc. and Neuralstem Inc.s return on assets, net margins and return on equity.

Risk & Volatility

Tenax Therapeutics Inc.s 1.4 beta indicates that its volatility is 40.00% more volatile than that of S&P 500. Neuralstem Inc.s 94.00% more volatile than S&P 500 which is a result of the 1.94 beta.

Liquidity

Tenax Therapeutics Inc.s Current Ratio is 11 while its Quick Ratio is 11. On the competitive side is, Neuralstem Inc. which has a 3.8 Current Ratio and a 3.8 Quick Ratio. Tenax Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Neuralstem Inc.

Insider and Institutional Ownership

Institutional investors owned 22.2% of Tenax Therapeutics Inc. shares and 4.9% of Neuralstem Inc. shares. Tenax Therapeutics Inc.s share owned by insiders are 4.73%. On the other hand, insiders owned about 1% of Neuralstem Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Tenax Therapeutics Inc. had bullish trend while Neuralstem Inc. had bearish trend.

Summary

Tenax Therapeutics Inc. beats Neuralstem Inc. on 5 of the 9 factors.

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companys stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See the rest here:
Reviewing Tenax Therapeutics Inc. (TENX)'s and Neuralstem Inc. (NASDAQ:CUR)'s results - MS Wkly